Veloxis Pharmaceuticals A/S (VELO) Announces Financial Results for the First Three Months of 2013
5/16/2013 6:17:00 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
HORSHOLM, Denmark, May 15, 2013 /PRNewswire/ --
•On 29 April, 2013 Veloxis submitted the MAA to the European Medicines Agency (EMA) seeking approval to market LCP-Tacro™ for the prevention of organ rejection in kidney transplant patients in the European Union. The MAA submission is based on the favorable results of the LCP-Tacro™ Phase III 3001 study in stable kidney transplant patients and data from an extensive Phase I and II clinical program. Veloxis expects the decision from the European Union in 2014.
Help employers find you! Check out all the jobs and post your resume.